Bian Yanqin, Chen Xi, Cao Hongyan, Xie Dong, Zhu Meiping, Yuan Nong, Lu Lu, Lu Bingjie, Wu Chao, Bahaji Azami Nisma Lena, Wang Zheng, Wang Huijun, Zhang Yeqing, Li Kun, Ye Guan, Sun Mingyu
Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Pudong New District, Shanghai, 201203, China.
Arthritis Institute of Integrated Traditional Chinese and Western Medicine, Shanghai Academy of Traditional Chinese Medicine, Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200052, China.
Chin Med. 2021 Nov 20;16(1):120. doi: 10.1186/s13020-021-00529-9.
Weifuchun (WFC), a Chinese herbal prescription consisting of Red Ginseng, Isodon amethystoides and Fructus Aurantii, is commonly used in China to treat a variety of chronic stomach disorders. The aim of the paper was to determine the effect of WFC on intestinal microbiota changes in precancerous lesions of gastric cancer (PLGC) patients.
PLGC patients of H. pylori negative were randomly divided into two groups and received either WFC tablets for a dose of 1.44 g three times a day or vitacoenzyme (Vit) tablets for a dose of 0.8 g three times a day. All patients were treated for 6 months consecutively. Gastroscopy and histopathology were used to assess the histopathological changes in gastric tissues before and after treatment. 16S rRNA gene sequencing was carried out to assess the effects WFC on intestinal microbiota changes in PLGC patients. Receiver Operating Characteristics (ROC) analysis was used to assess the sensitivity and specificity of different intestinal microbiota in distinguishing between PLGC patients and healthy control group.
Gastroscopy and histopathological results indicated that WFC could improve the pathological condition of PLGC patients, especially in the case of atrophy or intestinal metaplasia. The results of 16S rRNA gene sequencing indicated that WFC could regulate microbial diversity, microbial composition, and abundance of the intestinal microbiota of PLGC patients. Following WFC treatment, the relative abundance of Parabacteroides decreased in WFC group when compared with the Vit group. ROC analysis found that the Parabacteroides could effectively distinguish PLGC patients from healthy individuals with sensitivity of 0.79 and specificity of 0.8.
WFC could slow down the progression of PLGC by regulating intestinal microbiota abundance. Trial registration NCT03814629. Name of registry: Randomized Clinical Trial: Weifuchun Treatment on Precancerous Lesions of Gastric Cancer. Registered 3 August 2018-Retrospectively registered, https://register.clinicaltrials.gov/ NCT03814629.
胃复春（WFC）是一种由红参、香茶菜和枳壳组成的中药方剂，在中国常用于治疗多种慢性胃部疾病。本文旨在确定WFC对胃癌前病变（PLGC）患者肠道微生物群变化的影响。
将幽门螺杆菌阴性的PLGC患者随机分为两组，分别接受每日三次、每次1.44 g的WFC片或每日三次、每次0.8 g的复合辅酶（Vit）片治疗。所有患者连续治疗6个月。采用胃镜检查和组织病理学评估治疗前后胃组织的组织病理学变化。进行16S rRNA基因测序以评估WFC对PLGC患者肠道微生物群变化的影响。采用受试者工作特征（ROC）分析评估不同肠道微生物群在区分PLGC患者和健康对照组方面的敏感性和特异性。
胃镜检查和组织病理学结果表明，WFC可改善PLGC患者的病情，尤其是萎缩或肠化生情况。16S rRNA基因测序结果表明，WFC可调节PLGC患者肠道微生物群的多样性、微生物组成和丰度。WFC治疗后，与Vit组相比，WFC组副拟杆菌的相对丰度降低。ROC分析发现，副拟杆菌可有效区分PLGC患者和健康个体，敏感性为0.79，特异性为0.8。
WFC可通过调节肠道微生物群丰度减缓PLGC的进展。试验注册编号：NCT03814629。注册名称：随机临床试验：胃复春治疗胃癌前病变。于2018年8月3日注册——回顾性注册，https://register.clinicaltrials.gov/ NCT03814629 。
